Fifteen years of losartan: what have we learned about losartan that can benefit chronic kidney disease patients?
Losartan, the first AT1 receptor blocker (ARB), was FDA approved 15 years ago. During those years, researchers and clinicians have developed a growing base of knowledge on the benefits of losartan, particularly for hypertension and renal disease. These benefits include decreasing proteinuria, slowin...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2010
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3108782/ |